Press release from PR Newswire
Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
Friday, September 03, 2010
Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference09:30 EDT Friday, September 03, 2010TARRYTOWN, N.Y., Sept. 3 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010. The presentation is scheduled for 1:00 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through October 13, 2010. Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.Investor Relations914.email@example.comPeter DworkinCorporate Communications914.firstname.lastname@example.orgSOURCE Regeneron Pharmaceuticals, Inc.For further information: Michael Aberman, M.D., Investor Relations, +1-914-345-7799, email@example.com, or Peter Dworkin, Corporate Communications, +1-914-345-7800, firstname.lastname@example.org, both of Regeneron Pharmaceuticals, Inc.